| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.087 | 0.09 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.061 | 0.09 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.09 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | 0.073 | 0.09 |
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.09 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | -0.059 | 0.09 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | 0.062 | 0.09 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.09 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.09 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.065 | 0.09 |